Blog

Christian Rolfo: Important meeting on Drug Tolerance and Resistance in NSCLC

Photo taken from IASLC/X

Jul 11, 2024, 13:51

Christian Rolfo: Important meeting on Drug Tolerance and Resistance in NSCLC

Christian Rolfo, Associate Director of Clinical Research Center of Thoracic Oncology at The Tisch Cancer Institute at Mount Sinai Health System, shared the following post by International Association for the Study of Lung Cancer (IASLC) on X, adding the following:

“Important meeting on Drug Tolerance and Resistance in NSCLC. Please submit your abstract! Great opportunity to discuss on translational research. See you all in Washington DC!”

Quoting International Association for the Study of Lung Cancer (IASLC)’s post:

“Deadline Extended! Submit your abstract to dive deep into the mechanisms, biomarkers & models that drive our understanding/treatment of drug tolerance/resistance in NSCLC. Share your groundbreaking research. Contribute to the future of lung cancer therapy.”

Source: Christian Rolfo/X and IASLC/X

Abstract submission biomarkers cancer cancer therapy Christian Rolfo clinical research drug resistance drug tolerance IASLC Lung cancer Mount Sinai Health System. NSCLC OncoDaily Oncology Tisch Cancer Institute translational research Washington DC

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer